The Efficacy and Safety of Mesalamine and Probiotics in Mild-to-Moderate Ulcerative Colitis: A Systematic Review and Meta-Analysis

Chunying Tian, Yang Huang, Xiaoxia Wu, Chuhan Xu, Huaien Bu, and Hongwu Wang

Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China

Correspondence should be addressed to Huaien Bu; huaienbu@tjutcm.edu.cn and Hongwu Wang; tjwanghw55@163.com

Received 22 November 2019; Revised 19 January 2020; Accepted 15 February 2020; Published 28 March 2020

Academic Editor: Jairo Kennup Bastos

Copyright © 2020 Chunying Tian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To evaluate the efficacy and safety of mesalamine in conjunction with probiotics for ulcerative colitis.

Methods. Random controlled trials (RCTs) were searched in PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure, Wanfang, and VIP (VIP Database for Chinese Technical Periodicals) from inception to October 2019. Methodological quality was assessed by the Cochrane Collaboration tool. The quality of evidence was rated by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE). Data analysis was carried out in Review Manager 5.3. Results. A total of fifteen studies met the criteria for inclusion. Thirteen studies reported the clinical efficacy, three studies provided data on the clinical symptom scores, two trials reported disease activity index, and four studies evaluated endoscopic score. For ulcerative colitis (UC), mesalamine and probiotics had better clinical efficacy than mesalamine alone (≤8 weeks: RR = 1.12, 95% CI: 1.07–1.18, \(P < 0.0001\); >8 weeks: RR = 1.25, 95% CI: 1.11–1.41, \(P = 0.0003\)). On the clinical symptom scores, disease activity index, and endoscopic score, UC patients receiving mesalamine and probiotics had significant difference than patients receiving mesalamine alone (MD = −2.02, 95% CI: −3.28 to −0.76, \(P = 0.002\); MD = −1.20, 95% CI: −1.76 to −0.65, \(P < 0.001\); and MD = −0.42, 95% CI: −0.61 to −0.23, \(P < 0.0001\), respectively). There was no statistically significant difference in adverse events between the two groups (RR = 0.88, 95% CI: 0.54 to 1.43, \(P = 0.60\)). Conclusion. Our meta-analysis results supported that mesalamine and probiotics were effective and safe in treating ulcerative colitis.

1. Introduction

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) with onset most frequently in adults aged 30–40 years [1]. The worldwide incidence and prevalence of UC have been increasing over the last few decades [2]. The highest annual incidence of UC was 24.3 per 100,000 person-years in Europe, 6.3 per 100,000 person-years in Asia and the Middle East, and 19.2 per 100,000 person-years in North America [3]. Most patients with UC have a mild-to-moderate course characterized by suffering from a relapsing and remitting course [4, 5]. For the American Gastroenterological Association institute guideline on the management of mild-to-moderate ulcerative colitis [5], mild-to-moderate UC was defined as patients with <4–6 bowel movements per day, mild-to-moderate rectal bleeding, absence of constitutional symptoms, low overall inflammatory burden, and absence of features suggestive of high inflammatory activity, based on Truelove and Witt’s criteria [6] and the Mayo Clinic score [7]. Although the etiology of UC remains unclear, an excessive immune response to endogenous bacteria in genetically predisposed individuals may play an important role in the pathophysiology of UC [8–10].

The existing mainstay of therapy for mild-to-moderate UC is the 5-ASA class of medications, including mesalamine, sulfasalazine, and diazo-bonded 5-ASA [11]. Mesalamine is a first-line treatment for many patients with UC. It gives anti-inflammatory effects by increasing expression of peroxisome proliferator-activated receptors in gastrointestinal epithelial cells. Furthermore, it acts to inhibit COX enzymes, thus affecting prostaglandins and decreasing inflammation of the colon [12–16]. Unfortunately,
it is difficult to cure UC completely, with 74% of patients experiencing at least one relapse during 5-year observation in a prospective population-based cohort study [17]. Furthermore, taking these drugs could lead to the occurrence of various adverse effects [18]. Therefore, new therapeutic optimizations are required in order to improve clinical efficacy.

However, UC is characterized by periods of activity and UC patients can experience frequent relapses [5]. After the imbalance of gastrointestinal flora, the decrease of the number of beneficial bacteria such as caseating bacteria causes the patients' intestinal epithelial cells' lack of energy source, and the increase of harmful bacteria and pathogenic bacteria in the intestinal tract will cause hydrolytic protein and enterotoxin, which will damage the patients' intestinal mucosal cells, activate immune cells, increase intestinal mucosal permeability, and induce immune response [19]. Therefore, the treatment that is directly modulating the gut microbiota is an attractive therapeutic option for UC [20]. Probiotics contain viable microorganisms, sufficient amounts of which reach the intestine in an active state for them to exert positive health effects [21]. They mostly include lactic acid-producing bacteria, such as bifidobacteria and lactobacilli. Many studies showed that these probiotics modulated membrane permeability and the mucosal immune system [20, 22]. However, the sample size was relatively small, such that there was no definitive evidence as to whether probiotics were helpful. Thus, we performed a systematic review and meta-analysis based on a large data of RCTs, making the evidence more convincing.

2. Materials and Methods

2.1. Search Strategy. We performed a comprehensive literature search in the PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure, Wanfang, and VIP (VIP Database for Chinese Technical Periodicals) from inception to October 2019. The search terms used are as follows: mesalazine, mesalamine, probiotics, and ulcerative colitis. Reference list of included studies was also checked to identify potentially eligible studies. The identified studies were not constrained by language. Taking PubMed as an example, detailed search strategy was as follows:

#1 “mesalamine” [MeSH Terms] OR “mesalamine” [Title/Abstract] OR “mesalazine” [Title/Abstract]
#2 “probiotics” [MeSH Terms] OR “probiotics” [Title/Abstract]
#3 “colitis, ulcerative” [MeSH Terms] OR “colitis, ulcerative” [Title/Abstract]
#4 #1 AND #2 AND #3

2.2. Inclusion Criteria. Trials were selected based on the following inclusion criteria: (1) RCTs comparing mesalamine and probiotics with mesalamine alone; (2) patients diagnosed definitely as mild-to-moderate ulcerative colitis with no limits on their sex, age, or case resources; (3) trials reporting the clinical efficacy, the clinical symptom scores, disease activity index (DAI), endoscopic score, or adverse events as outcome. The criteria of clinical efficacy were as follows: effectiveness meant that the clinical symptoms disappeared basically and endoscopy showed normal or mild inflammation; inefﬁcience meant that there was no change in the clinical symptoms and endoscopy after treatment.

And exclusion criteria were (1) non-mild-to-moderate patients; (2) noninterventional studies, such as traditional review, systematic review and meta-analysis, case reports, cohort study, guideline or recommendation; (3) nonclinical studies, such as animal studies, theoretical research; (4) ongoing trial; (5) irrelevant studies; (6) repeated studies; and (7) studies with only abstract.

2.3. Data Extraction and Assessment of Quality. Two researchers (Chunying Tian and Yang Huang) independently performed the data extraction in a standard excel sheet. When disagreement was evident, a third researcher (Hongwu Wang) resolved the issue. For each study, the following information was extracted: the first author, publication year, study design, study location, sex, age, the course of disease, sample size, the dosage of treatment, treatment period, and outcome.

The methodological quality of included studies was assessed independently by two researchers (Chunying Tian and Xiaoxia Wu) based on the Cochrane Collaboration tool with the following domains: (1) generation of random sequence; (2) allocation concealment; (3) blinding of participants and personnel; (4) blinding of outcome assessment; (5) selective reporting; (6) incomplete outcome data; and (7) other bias. The results were assessed as high risk, unclear risk, and low risk. Besides, the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) [23] was used to rate the quality of evidence by the consensus of two authors (Chunying Tian and Huaien Bu).

2.4. Statistical Analysis. Statistical analysis was carried out in the Review Manager 5.3 (RevMan 5.3). Continuous data were expressed as mean difference (MD) with 95% conﬁdence interval (CI), and the relative risk (RR) with 95% CI was calculated in the dichotomous data [24]. Heterogeneity of included data was evaluated with the use of the chi-square test and I² statistic. The DerSimonian and Laird random-effects model was used when high heterogeneity was assessed (I² > 50% or \( P < 0.10 \)). Otherwise, the Mantel–Haenszel fixed-effects model was used for statistical analysis [25, 26]. Sensitivity analysis was conducted to assess the stability of pooled results. Publication bias was observed by an inverted funnel plot [27].

3. Results

3.1. Screening Process. A total of 419 related studies were initially retrieved from six databases, of which 208 were excluded due to duplication. Titles and abstracts of 211 studies were screened for inclusion. Full texts of 97 studies were read, and 15 studies [19, 28–41] met our inclusion criteria. The flow chart of study selection is presented in Figure 1.
3.2. General Characteristics of Included Studies. The included studies were published from 2008 to 2019. The sample size ranged from 34 to 360, with a total of 1433 patients. Fifteen studies involved four different ways of probiotics, including Bifid Triple Viable Capsules, *Bifidobacterium TriPlex*, *Lactobacillus* and *Bifidobacterium quadruple viable tablet*. The treatment period of fifteen studies ranged from 4 to 24 weeks. Thirteen reports [19, 28–30, 32–38, 40, 41] evaluated the clinical efficacy. Three studies [33, 36, 39] provided data on the clinical symptom scores. Four trials [33, 36, 39, 41] reported disease activity index. Two trials [36, 39] estimated endoscopic score. Twelve studies [19, 28, 29, 31–33, 35–40] reported adverse events. General characteristics of included fifteen studies are summarized in Table 1.

3.3. Assessment of Quality. All studies mentioned randomization and were rated as low risk of bias for this item. In assessing the risk of allocation concealment, four studies [29, 36, 37, 41] using random number table method were rated as high risk of bias for this item. Blindness was unclear in most studies. Only one study [19] mentioned single blindness and was assessed as low risk of bias. As to incomplete outcome data, one study [41] was rated as high risk of bias because there was missing data in results. Two studies [35, 41] were assessed as high risk of bias for selective reporting. The baseline of one study [41] was imbalanced. Therefore, it was rated as high risk of bias in other bias. The risk of bias assessment in the studies is presented in Figure 2.

3.4. Pooled Results

3.4.1. Clinical Efficacy. Thirteen studies [19, 28–30, 32–38, 40, 41] evaluated the clinical efficacy, which involved a total of 1294 patients. There was no heterogeneity between experimental group and control group when the course of treatment was less than 8 weeks ($P = 0.87$, $I^2 = 0\%$); thus, a fixed-effects model was used. Eleven studies [19, 28–30, 32, 33, 35, 36, 38, 40, 41] found that mesalamine and probiotics were superior to mesalamine alone on the clinical efficacy within 8 weeks (RR = 1.12, 95% CI: 1.07 to 1.18, $P < 0.0001$). And there was no statistical heterogeneity in the results when the course of treatment was more than 8 weeks ($P = 0.88$, $I^2 = 0\%$); thus, a fixed-effects model was used. Two studies [34, 37] also found that mesalamine and probiotics were superior to mesalamine alone on the clinical efficacy more than 8 weeks (RR = 1.25, 95% CI: 1.11 to 1.41, $P = 0.0003$) (Figure 3).
| Author, Publication year | Study design | Study location | Sex (M/F) | Age (year) (mean ± SD) or range | The course of disease (mean ± SD) (or range) | Sample size | The dosage of treatment | Treatment period (week) | Outcome |
|--------------------------|-------------|----------------|----------|-------------------------------|---------------------------------------------|-------------|------------------------|---------------------|---------|
| Wang 2018 [28]           | RCT         | China          | T: 32/31 C: 33/30 | T: 32.49 ± 3.76 C: 32.61 ± 4.04 | T: 16.75 ± 4.46 m C: 16.94 ± 4.68 m | 126         | Mesalamine 0.5 g, TID + Bifid Triple Viable Capsules 3 capsules, BID Mesalamine 1.5 g, TID + Bifid Triple Viable Capsules 2 capsules, TID | 4       | 🟢🟢 |
| Wang et al. 2013 [29]    | RCT         | China          | T: 19/14 C: 19/11 | — | T: 0.5~5.5y C: 0.5~6y | 63         | Mesalamine 1.5 g, TID | 8       | 🟢🟢 |
| Chen et al. 2019 [30]    | RCT         | China          | T: 25/25 C: 28/22 | T: 69.26 ± 9.30 C: 69.11 ± 9.14 | T: 3.41 ± 2.37y C: 3.63 ± 2.50y | 100        | Mesalamine 1.0 g, QID + Bifidobacterium tripex 0.42 g, TID Mesalamine 0.5~1.0 g, TID + Bifid Triple Viable Capsules 0.42 g, TID | 8       | 🟢 |
| Luo 2008 [31]            | RCT         | China          | T: 25/14 C: 19/9 | T: 19~59 C: 21~69 | T: 0.5~13y C: 0.5~11y | 67         | Mesalamine 1.0 g, QID | 4       | 🟢🟢 |
| Wang 2013 [32]           | RCT         | China          | — | T: 20~75 C: 17~72 | T: 0.5~5.5y C: 0.5~6y | 70         | Mesalamine 1.0 g, QID + combined Bifidobacterium and Lactobacillus 2 g, TID Mesalamine 1.0 g, QID + Bifidobacterium tripex 0.42 g, TID Mesalamine 1.0 g, QID + Bifidobacterium and Lactobacillus 2 g, TID Mesalamine 1.0 g, QID + Bifidobacterium tripex 0.42 g, TID | 8       | 🟢🟢 🔴 🔴 |
| Zhang 2017 [33]          | RCT         | China          | T: 15/10 C: 14/11 | T: 42.3 ± 2.1 C: 44.9 ± 3.7 | — | 50         | Mesalamine 1.0 g, QID + Bifidobacterium tripex 0.42 g, TID Mesalamine 1.0 g, QID + Bifidobacterium tripex 0.42 g, TID | 8       | 🟢🟢 🔴 🔴 |
| Wang 2016 [34]           | RCT         | China          | T: 19/16 C: 21/14 | T: 45.3 ± 9.7 C: 44.6 ± 9.4 | T: 5.3 ± 1.5y C: 4.8 ± 1.2y | 70         | Mesalamine 1.0 g, TID + Lactobacillus 100 ml, TID Mesalamine 1.0 g, QID + Bifid Triple Viable Capsules, 5~6 capsule, BID Mesalamine 1.0 g, QID + Bifid Triple Viable Capsules, 2~4 capsule, BID Mesalamine 1.0 g, QID + Bifid Triple Viable Capsules, 2~4 capsule, BID | 24      | 🟢 |
| Xing et al. 2017 [19]    | RCT         | China          | T: 29/26 C: 28/27 | T: 34.0 ± 5.0 C: 33.4 ± 4.5 | T: 4.5 ± 0.5y C: 4.0 ± 0.5y | 110        | Mesalamine 1.0 g, QID | 8       | 🟢🟢 |
| Liu et al. 2010 [35]     | RCT         | China          | — | — | — | 58         | Mesalamine 1.0 g, QID | 4       | 🟢🟢 |
| Li et al. 2017 [36]      | RCT         | China          | T: 14/12 C: 13/12 | T: 43.2 ± 5.1 C: 42.6 ± 4.9 | — | 51         | Mesalamine 1.0 g, QID + Bifidobacterium tripex 0.42 g, TID Mesalamine 1.0 g, TID + Bifid Triple Viable Capsules 0.42 g, TID Mesalamine 1.0 g, TID + Bifid Triple Viable Capsules 0.42 g, TID | 8       | 🟢🟢 🔴 🔴 |
| Gao 2018 [37]            | RCT         | China          | T: 33/25 C: 32/26 | T: 35.26 ± 6.26 C: 35.67 ± 6.14 | T: 5.52 ± 2.02y C: 5.74 ± 1.68y | 116        | Mesalamine 1.0 g, TID | 12      | 🟢🟢 |
| Author, Publication year | Study design | Study location | Sex (M/F) | Age (year) | Study duration (week) | The course of remission | The clinical symptom scores | Disease activity index (DAI) | Endoscopic score | Adverse events |
|--------------------------|--------------|----------------|-----------|------------|-----------------------|------------------------|---------------------------|--------------------------|-----------------|---------------|
| Cheng 2018 [38]          | RCT          | China          | T: 22/21  | T: 39.5 ± 3.3 | 3.6 ± 0.5 y           | 34                     | 24 ± 6                    | 0.8 ± 0.2                | 71.0 ± 1.2      | 3.5 ± 1.8 |
| Liu et al. 2013 [39]     | RCT          | China          | T: 16/20  | T: 49.36 ± 2.62 | 72                   | 24 ± 5                 | 1.7 ± 0.5                | 8 ± 3                    | 7 ± 2           | 2 ± 3         |
| Zhou 2019 [40]           | RCT          | China          | T: 13/7   | T: 19 ± 5.6 | 34                   | 2 ± 3                  | 1.8 ± 0.5                | 8 ± 3                    | 7 ± 2           | 2 ± 3         |
| Huang et al. 2018 [41]   | RCT          | China          | T: 90/90  | T: 42.2 ± 9.4 | 5.5 ± 1.8            | 360                   | 24 ± 6                  | 0.8 ± 0.2                | 71.0 ± 1.2      | 3.5 ± 1.8 |

Note: —: not mentioned; ①: clinical efficacy; ②: the clinical symptom scores; ③: disease activity index (DAI); ④: endoscopic score; and ⑤: adverse events.
3.4.2. Clinical Symptom Scores. Three studies [33, 36, 39] totaling 173 patients provided data on the clinical symptom scores. Among the 173 patients, mesalamine and probiotics were used as an experimental therapy in 87 patients, and 86 patients were treated by mesalamine. There was significant heterogeneity between experimental group and control group ($P < 0.00001$, $I^2 = 93\%$); thus, a random-effects model was used. Compared with mesalamine alone, the combination with probiotics was significantly different on the clinical symptom scores (MD = $-2.02$, 95% CI: $-3.28$ to $-0.76$, $P < 0.002$) (Figure 4). After excluding one study (Zhang [33]), there was no heterogeneity ($P = 0.42$, $I^2 = 0\%$); thus, a fixed-effects model was used. Sensitivity analysis indicated that mesalamine and probiotics were significantly different on the DAI compared with mesalamine alone (MD = $-1.32$, 95% CI: $-1.58$ to $-1.07$, $P < 0.00001$). And the results of the DAI were stable.

3.4.3. Disease Activity Index (DAI). Four trials [33, 36, 39, 41] reported disease activity index, which involved a total of 533 UC patients, 267 of them used mesalamine and probiotics for therapy, and 266 patients were treated by mesalamine. After performing a meta-analysis, there was significant heterogeneity between experimental group and control group ($P < 0.00001$, $I^2 = 94\%$); thus, a random-effects model was used. The result showed that there was significant difference between the two groups (MD = $-1.20$, 95% CI: $-1.76$ to $-0.65$, $P < 0.001$) (Figure 5). After excluding studies (Huang [41] and Liu et al. [39]), there was no heterogeneity ($P = 0.42$, $I^2 = 0\%$); thus, a fixed-effects model was used. Sensitivity analysis indicated that mesalamine and probiotics were significantly different on the DAI compared with mesalamine alone (MD = $-1.32$, 95% CI: $-1.58$ to $-1.07$, $P < 0.00001$). And the results of the DAI were stable.

3.4.4. Endoscopic Score. Two trials [36, 39] involving 123 UC patients with probiotics in the adjuvant therapy analyzed the endoscopic score. There was no statistically significant heterogeneity ($P = 0.21$, $I^2 = 35\%$); thus, a fixed-effects model was used. Significant differences in UC patients were observed between the two groups, suggesting that the
efficacy of probiotics in the adjuvant therapy of UC in the experimental group may be better than that in the control group (MD = -0.42, 95% CI: -0.61 to -0.23, P < 0.0001) (Figure 6).

3.4.5. Adverse Events. Twelve trials [19, 28, 29, 31–33, 35–40] with 875 participants reported adverse events. There was no heterogeneity in the results (P = 1.00, I² = 0%); thus, a fixed-effects model was used. Statistically significant difference was
not found in the pooling of data between two groups (RR = 0.88, 95% CI: 0.54–1.43, P = 0.60), suggesting that the safety of mesalamine and probiotics for UC was similar with mesalamine alone (Figure 7).

3.4.6. Publication Bias. There was an uneven distribution and light asymmetry in the funnel plot, which meant publication bias in the clinical efficacy between the experimental group and the control group may exist. The funnel plot is presented in Figure 8.

3.4.7. Quality of the Evidence. The GRADE system was used to assess the quality of the evidence. In comparing the efficacy of mesalamine and probiotics with mesalamine, the quality of evidence is low in the outcome of the clinical efficacy. This is due to serious imprecision and reporting bias. The quality of evidence is very low in the three outcomes: the clinical symptom scores, DAI, and endoscopic score. This is due to the risk of bias, serious inconsistency, and serious imprecision. For the outcome “adverse events,” the quality of evidence is moderate.
because of the risk of bias. The summary of findings is presented in Figure 9.

4. Discussion

Continued improvements in the management of UC are needed to enable the most effective treatment possible for this disease. This is particularly important for UC of a mild-to-moderate severity, as the prevalence and incidence of UC are increasing worldwide [42]. The pathological and physiological mechanism of UC was complicated. It was reported that the intestinal flora for most patients with UC had changed, compared with normal healthy people [43]. The number of *Bifidobacterium*, *Helicobacter spiralis*, and *Pseudomonas* had decreased, while the number of *Entero-coccus* and *Bacillus* increased. Therefore, correcting the imbalance of bacterial flora through probiotics is a possible treatment [44]. Many studies indicated that the mechanism of probiotics for UC patients was unclear, and the effect of mesalamine was obvious [45]. The possible mechanisms of

### Table: Mesalamine and probiotics vs mesalamine for ulcerative colitis

| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No. of participants (studies) | Quality of the evidence (GRADE) | Comments |
|----------|-----------------------------------------|--------------------------|------------------------------|-------------------------------|----------|
| **Clinical efficacy (≤ 8 weeks)** | | RR 1.12 (1.07 to 1.18) | 1108 (11 studies) | Moderate | 888 per 1000 883 per 1000 (843 to 930) |
| Study population | 788 per 1000 | 883 per 1000 | | | |
| Medium-risk population | 800 per 1000 | 896 per 1000 (856 to 944) | | | |
| **Clinical efficacy (>8 weeks)** | | RR 1.25 (1.11 to 1.41) | 186 (2 studies) | Very low | 896 per 1000 894 per 1000 (847 to 1000) |
| Study population | 763 per 1000 | 954 per 1000 (847 to 1000) | | | |
| Medium-risk population | 759 per 1000 | 949 per 1000 (842 to 1000) | | | |
| **The clinical symptom scores** | The mean The clinical symptom scores in the intervention groups was 1.87 lower (2.2 to 1.55 lower) | RR 0.88 (0.54 to 1.43) | 875 (12 studies) | Moderate | 70 per 1000 62 per 1000 (38 to 100) |
| Study population | 70 per 1000 | 62 per 1000 (38 to 100) | | | |
| Medium-risk population | 63 per 1000 | 55 per 1000 (34 to 90) | | | |
| **Disease activity index (DAI)** | The mean Disease activity index (DAI) in the intervention groups was 1.32 lower (1.58 to 1.07 lower) | RR 0.88 (0.54 to 1.43) | 123 (2 studies) | Very low | 896 per 1000 894 per 1000 (847 to 1000) |
| **Endoscopic score** | The mean Endoscopic score in the intervention groups was 0.42 lower (0.61 to 0.23 lower) | RR 0.88 (0.54 to 1.43) | 123 (2 studies) | Very low | 896 per 1000 894 per 1000 (847 to 1000) |

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

**Figure 9:** The Summary of findings.
probiotics in the therapy of UC mainly include the following: (1) to prevent pathogen infiltration by restraining bacterial adherence and bacteria translocation, or to produce antibacterial substances that inhibit the growth pathogenic bacteria; (2) to improve the function of epithelial mucosal barrier; (3) to regulate the mucosal immune response; and (4) to reduce the secretion of proinflammatory factors [46]. Therefore, if probiotics was used when mesalamine was taken, the treatment plan would regulate the intestinal flora, curb the inflammatory responses, and improve therapeutic efficacy [46]. Furthermore, the advantages of probiotics therapy include overcoming gastrointestinal tract infections, resisting stomach acid, bile, and antibiotics, and modifying immune processes to destroy invading microorganisms [47].

The present study comprehensively and systematically reviewed the current available literature and found the following: (1) For mild-to-moderate UC patients, mesalamine in conjunction with probiotics had more significant therapeutic potential than mesalamine alone on the clinical efficacy no matter the treatment period was less than eight weeks or more, which indicated it could improve the clinical efficacy for mild-to-moderate UC patients. (2) Mesalamine and probiotics had significant difference for UC patients on the clinical symptom scores than mesalamine alone, which showed that clinical symptom scores were decreased and the clinical symptoms were alleviated, such as diarrhea, mucosa bloody stool, and abdominal pain. (3) Patients who took both mesalamine and probiotics had better results on the DAI than those who took mesalamine alone, which meant that the DAI was decreased and the frequency of diarrhea, mucosal manifestations, and bleeding was relieved. (4) For UC patients, significant differences on the endoscopic score were observed between the experimental group and the control group, which demonstrated that the condition of mucosa under endoscopy was improved. (5) Adverse events reported in these studies included nausea, abdominal extension, abdominal discomfort, headache, rash, fever, and liver dysfunction. The safety of mesalamine and probiotics for UC was similar to mesalamine alone, suggesting that mesalamine and probiotics did not increase the risk of drug use and had high safety. (6) In the quality assessment, the included studies were generally low risk of bias. And funnel plot showed there was light publication bias. (7) According to the GRADE assessment, the clinical efficacy was judged as low quality of evidence, the clinical symptom scores, DAI and endoscopic score were judged as very low quality of evidence, and adverse event was judged as moderate quality of evidence. Therefore, clinicians need to consider comprehensively when mesalamine and probiotics are used for mild-to-moderate ulcerative colitis patients, due to the complexity of clinical decision-making.

This review had certain limitations which were worthy of consideration. Primarily, there were no specific descriptions of generation of random sequence, allocation concealment, and blindness in most studies. Therefore, methodological limitations and the small sample size reduced the reliability of results. In addition, rating results of GRADE tool showed that three outcomes were rated as very low quality of the evidence. Two outcomes were, respectively, rated as low and moderate quality of the evidence. Thus, more well-designed and large-scale studies are warranted. Besides, there was a visible heterogeneity on the clinical symptom scores, DAI, and endoscopic score. According to the sensitivity analysis, the possible explanations about heterogeneity were presented as follows: the baseline difference of the included studies and the small sample size may contribute to the heterogeneity. Finally, the patients of included studies were Chinese, which limited generalizability of findings and caused publication bias. In fact, the inverted funnel plot indicated that there was a light publication bias, which may influence the stability of results.

5. Conclusion
In conclusion, our meta-analysis results supported that mesalamine and probiotics were effective and safe treatment for ulcerative colitis. Although the treatment plan appears to be effective and safe in this meta-analysis, further well-designed, more rigorous, and standardized studies are needed to confirm our results.

Data Availability
This paper contains data that support the results of this study.

Disclosure
The funders had no role in the study design, data extraction and analysis, decision to publish, and preparation of the paper.

Conflicts of Interest
The authors have no conflicts of interest regarding the publication of this paper.

Authors’ Contributions
Chunying Tian and Yang Huang are the co-first authors.

Acknowledgments
The authors gratefully acknowledge the support from the National Key Basic Research and Development Plan of China (2011CB505406).

References
[1] M. Fumery, S. Singh, P. S. Dulai, C. Gower-Rousseau, L. Peyrin-Biroulet, and W. J. Sandborn, “Natural history of adult ulcerative colitis in population-based cohorts: a systematic review,” Clinical Gastroenterology and Hepatology, vol. 16, no. 3, pp. 343–356, 2018.
[2] B. C. d. Silva, A. C. Lyra, R. Rocha, and G. O. Santana, “Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis,” World Journal of Gastroenterology, vol. 20, no. 28, pp. 9458–9467, 2014.
[3] N. A. Molodecky, I. S. Soon, D. M. Rabi et al, “Increasing incidence and prevalence of the inflammatory bowel diseases
with time, based on systematic review,” Gastroenterology, vol. 142, no. 1, pp. 46–54, 2012.

[4] J. Torres, V. Billouud, D. B. Sachar, L. Peyrin-Biroulet, and J.-F. Colombel, “Ulcerative colitis as a progressive disease: the forgotten evidence,” Inflammatory Bowel Diseases, vol. 18, no. 7, pp. 1356–1363, 2012.

[5] C. W. Ko, S. Singh, J. D. Feuerstein et al., “AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis,” Gastroenterology, vol. 156, no. 3, pp. 748–764, 2019.

[6] S. C. Truelove and L. J. Witts, “Cortisone in ulcerative colitis,” BMJ, vol. 2, no. 4947, pp. 1041–1048, 1955.

[7] K. W. Schroeder, W. J. Tremaine, and D. M. Ilstrup, “Coated oral 5-minosaliclyc acid therapy for mildly to moderately active ulcerative colitis,” New England Journal of Medicine, vol. 317, no. 26, pp. 1625–1629, 1987.

[8] B. Khor, A. Gardet, and R. J. Xavier, “Genetics and pathogenesis of inflammatory bowel disease,” Nature, vol. 474, no. 7351, pp. 307–317, 2011.

[9] A. D. Kostic, R. J. Xavier, and D. Gevers, “The microbiome in inflammatory bowel disease: current status and the future ahead,” Gastroenterology, vol. 146, no. 6, pp. 1489–1499, 2014.

[10] A. W. Steen, C. M. Mela, J. O. Lindsay, B. G. Gazzard, and M. R. Goodier, “Increased proportion of CD16+ NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment,” Alimentary Pharmacology & Therapeutics, vol. 33, no. 1, pp. 115–126, 2011.

[11] X. Shi, Q. Chen, and F. Wang, “Mesenchymal stem cells for the treatment of ulcerative colitis: a systematic review and meta-analysis of experimental and clinical studies,” Stem Cell Research & Therapy, vol. 10, no. 1, p. 266, 2019.

[12] A. Algaba, I. Guerra, A. Garcia García de Paredes et al., “What is the real-life maintenance mesalazine dose in ulcerative colitis?” Revista Española de Enfermedades Digestivas, vol. 109, pp. 114–121, 2017.

[13] A. Grucela and R. M. Steinhagen, “Current surgical management of ulcerative colitis,” Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, vol. 76, no. 6, pp. 606–612, 2009.

[14] N. J. Talley, M. T. Abreu, J.-P. Achkar et al., “An evidence-based systematic review on medical therapies for inflammatory bowel disease,” American Journal of Gastroenterology, vol. 106, pp. S2–S25, 2011.

[15] A. C. Ford, J.-P. Achkar, K. J. Khan et al., “Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis,” American Journal of Gastroenterology, vol. 106, no. 4, pp. 601–616, 2011.

[16] C. Rousseaux, B. Lefebvre, L. Dubuquoy et al., “Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-γ-,” The Journal of Experimental Medicine, vol. 201, no. 8, pp. 1205–1215, 2005.

[17] A. Rönntblom, T. Holmström, H. Tanghøj, U. Karlbom, M. Thörn, and D. Sjöberg, “Low colonectomy rate five years after diagnosis of ulcerative colitis. Results from a prospective population-based cohort in Sweden (ICURE) diagnosed during 2005–2009,” Scandinavian Journal of Gastroenterology, vol. 51, no. 11, pp. 1339–1344, 2016.

[18] E. Troncone and G. Monteleone, “The safety of non-biological treatments in ulcerative colitis,” Expert Opinion on Drug Safety, vol. 16, no. 7, pp. 779–789, 2017.

[19] Y. F. Xing and X. M. Lei, “Efficacy of probiotics combined with mesalazine in the treatment of ulcerative colitis,” Clinical Research and Practice, vol. 2, no. 14, pp. 22-23, 2017.

[20] H. Tamaki, H. Nakase, S. Inoue et al., “Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: a randomized, double-blinded, placebo-controlled multicenter trial,” Digestive Endoscopy, vol. 28, no. 1, pp. 67–74, 2016.

[21] F. Guarnier, M. E. Sanders, R. Eliaikim et al., “Probiotics and prebiotics,” World Gastroenterology Organisation Global Guideline, vol. 80, pp. 113–117, 2017.

[22] V. Lorenzo-Zúñiga, E. Llop, C. Suárez et al., “L31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life,” World Journal of Gastroenterology, vol. 20, no. 26, pp. 8709–8716, 2014.

[23] G. H. Guyatt, A. D. Oxman, G. E. Vist et al., “GRADE: an emerging consensus on rating quality of evidence and strength of recommendations,” BMJ, vol. 336, no. 7650, pp. 924–926, 2008.

[24] R. Dersimionian and N. Laird, “Meta-analysis in clinical trials,” Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986.

[25] J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” BMJ, vol. 327, no. 7414, pp. 557–560, 2003.

[26] J. P. T. Higgins and S. G. Thompson, “Quantifying heterogeneity in a meta-analysis,” Statistics in Medicine, vol. 21, no. 11, pp. 1539–1558, 2002.

[27] M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” BMJ, vol. 315, no. 7109, pp. 629–634, 1997.

[28] Y. F. Wang, “Effect of mesalazine enteric coated tablets combined with probiotics on ulcerative colitis,” Clinical Practice of Integrated Traditional Chinese and Western Medicine, vol. 18, no. 11, pp. 20–22, 2018.

[29] R. Wang, H. M. Xu, and B. H. Zhang, “Effect of combination of mesalazine and intestinal probiotics in the treatment of ulcerative colitis,” Journal of Qiqihar Medical College, vol. 34, no. 17, pp. 2547-2548, 2013.

[30] Y. P. Chen and F. Han, “Effect of mesalazine combined with probiotics on cytokine level in elderly patients with moderate active ulcerative colitis,” Chinese Journal of Gerontology, vol. 39, no. 10, pp. 2383–2387, 2019.

[31] Y. Luo, Efficacy of Mesalazine Combined with Probiotics in the Treatment of Ulcerative Colitis, Shandong University, Jinan, China, 2008.

[32] H. Y. Wang, “Efficacy of mesalazine combined with probiotics in the treatment of mild to moderate ulcerative colitis,” Shaanxi Medical Journal, vol. 42, no. 7, pp. 921–922, 2013.

[33] H. A. Zhang, “Efficacy and safety evaluation of probiotics and mesalazine in the treatment of mild to moderate active ulcerative colitis,” Electronic Journal of Clinical Medicine, vol. 4, no. 82, pp. 16048–16050, 2017.

[34] H. B. Wang, “Effect of probiotics combined with mesalazine on Hb, PCV and ALB levels in patients with mild to moderate active ulcerative colitis,” Chinese and Foreign Women's Health Medicine, vol. 20, no. 1, pp. 924–926, 2011.

[35] M. X. Li, L. Zeng, and Q. Shu, “Efficacy and safety of probiotics combined with mesalazine in the treatment of mild to moderate active ulcerative colitis,” Journal of Qiqihar Medical College, vol. 34, no. 17, pp. 2547-2548, 2013.

[36] K. X. Li, L. Zeng, and Q. Shu, “The efficacy and safety of probiotics combined with mesalazine in the treatment of mild to moderate active ulcerative colitis,” Chinese Medical Innovation, vol. 14, no. 8, pp. 56–59, 2017.

[37] F. R. Gao, “Efficacy and safety analysis of probiotics combined with mesalazine in the treatment of mild and moderate active ulcerative colitis,” Special Health, vol. 7, no. 24, pp. 64-65, 2018.
[38] Z. H. Cheng, “Clinical efficacy of probiotics combined with mesalazine in the treatment of mild to moderate ulcerative colitis,” *Journal of Imaging Research and Medical Applications*, vol. 2, no. 18, pp. 248-249, 2018.

[39] W. Y. Liu, H. Qiu, Y. M. Li et al., “Clinical efficacy of probiotics combined with mesalazine in the treatment of mild to moderate ulcerative colitis,” *Chinese Clinical Medicine*, vol. 20, no. 2, pp. 150-151, 2013.

[40] X. J. Zhou, “Efficacy of probiotics combined with mesalazine in the treatment of ulcerative colitis,” *Journal of Jiangsu University (Medical Edition)*, vol. 19, no. 4, pp. 354–356, 2019.

[41] M. Huang, Z. Chen, C. Lang et al., “Efficacy of mesalazine in combination with bifid triple viable capsules on ulcerative colitis and the resultant effect on the inflammatory factors,” *Pakistan Journal of Pharmaceutical Sciences*, vol. 31, no. 6, pp. 2891–2895, 2018.

[42] S. Danese, R. Banerjee, J. F. Cummings et al., “Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i support therapy-access to rapid treatment (iSTART) approach,” *Intestinal Research*, vol. 16, no. 4, pp. 522–528, 2018.

[43] S. Sha, B. Xu, X. Wang et al., “The biodiversity and composition of the dominant fecal microbiota in patients with Inflammatory bowel disease,” *Diagnostic Microbiology and Infectious Disease*, vol. 75, no. 3, pp. 245–251, 2013.

[44] S. Ahrne and M.-L. J. Hagslatt, “Effect of lactobacilli on paracellular permeability in the gut,” *Nutrients*, vol. 3, no. 1, pp. 104–117, 2011.

[45] L. A. A. P. Derikx, L. A. Dieleman, and F. Hoentjen, “Probiotics and prebiotics in ulcerative colitis,” *Best Practice & Research Clinical Gastroenterology*, vol. 30, no. 1, pp. 55–71, 2016.

[46] L. Peng, Y. Zhong, A. Wang, and Z. Jiang, “Probiotics combined with aminosalicylic acid affiliates remission of ulcerative colitis: a meta-analysis of randomized controlled trial,” *Bioscience Reports*, vol. 39, no. 1, Article ID BSR20180943, 2019.

[47] C. W. Van Niel, C. Feudtner, M. M. Garrison, and D. A. Christakis, “Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis,” *Pediatrics*, vol. 109, no. 4, pp. 678–684, 2002.